Respiratory Medicine
Volume 98, Issue 10 , Pages 990-999, October 2004

Single-isomer R-salbutamol is not superior to racemate regarding protection for bronchial hyperresponsiveness

  • Kerstin Naidu Sjöswärd

      Affiliations

    • Department of Anaesthesiology, Faculty of Health, Institute of Medicine and Care, University Hospital, SE-581 85 Linköping, Sweden
    • Corresponding Author InformationCorresponding author. Fax: +46-13-22-18-09
  • ,
  • Mounira Hmani

      Affiliations

    • Faculty of Medicine, Laboratory of Human Molecular Genetics, Sfax, Tunisia
    • Department of Cell Biology, Faculty of Health, Linköping, Sweden
  • ,
  • Anette Davidsson
  • ,
  • Peter Söderkvist

      Affiliations

    • Department of Cell Biology, Faculty of Health, Linköping, Sweden
  • ,
  • Birgitta Schmekel

      Affiliations

    • Department of Clinical Physiology, Faculty of Health, Linköping, Sweden

Received 30 October 2003; accepted 3 March 2004. published online 19 August 2004.

Abstract 

Bronchial hyper-reactivity (BHR) has been suggested to follow cessation of regular medication with racemic salbutamol. This study aimed at investigating the effects from medication with R,S- and R-salbutamol on bronchial response to provocation with isocapnic hyperventilation of cold air (IHCA).

Twenty-six patients with mild to moderate asthma were enrolled in a double-blind, randomised, cross-over study. Bronchial response to provocation was measured before and after 1 week's medication. Doses of 0.63mg R-salbutamol or 1.25mg R/S-salbutamol were inhaled three times daily during medication-weeks and a wash-out week intervened. Tests were performed 6h after the last dose of test drug. Impulse oscillometry and forced expiratory volume during one second were methods used to identify bronchial response to provocation. Two patients withdrew from the investigation due to side-effects, one from R- the other from R,S-salbutamol.

Comparable resting bronchial conditions were indicated by differences in baseline lung function values of <2% between study days. No statistically significant medication-dependent differences in BHR could be demonstrated between treatment groups. However, 15 patients exhibited higher (P=0.03) post-treatment BHR after pure R-salbutamol than after R,S-salbutamol. Furthermore, plasma concentrations of R-salbutamol tended to be lower (P=0.08) after medication with R- than after R,S-salbutamol despite equal doses of R-salbutamol given during the two separate treatment periods. We also found that considerable amounts of S-salbutamol were retrieved in plasma after medication with pure R-salbutamol.

We conclude that we were unable to demonstrate favourable effects of R-salbutamol over R,S-salbutamol regarding response to provocation with IHCA after regular medication of 1 week's duration.

Keywords:  Bronchial hyperresponsiveness, Salbutamol, Enantiomer, Asthma, IOS

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0954-6111(04)00108-8

doi:10.1016/j.rmed.2004.03.005

Respiratory Medicine
Volume 98, Issue 10 , Pages 990-999, October 2004